China SXT Pharmaceuticals, Inc.
SXTC Healthcare Drug Manufacturers Specialty & Generic
China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
Follow SXTC
China SXT Pharmaceuticals, Inc. (SXTC) Piotroski F-score
China SXT Pharmaceuticals, Inc.'s Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2022.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | (1.00) |
| FY2022 | 4 | (1.00) |
| FY2021 | 5 | 1.00 |
| FY2020 | 4 | 0.00 |
| FY2019 | 4 | (4.00) |
| FY2018 | 8 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (22.00%) | (14.75%) | Fail | 0 |
| Positive operating cash flow | (4.02m) | (2.35m) | Fail | 0 |
| Rising return on assets | (22.00%) | (14.75%) | Fail | 0 |
| Cash flow above net income | 2.19m | 958.40k | Pass | 1 |
| Falling long-term leverage | 0.02 | 0.00 | Fail | 0 |
| Rising current ratio | 7.93 | 3.54 | Pass | 1 |
| No new shares issued | 8,500 | 100 | Fail | 0 |
| Rising gross margin | 21.85% | 21.10% | Pass | 1 |
| Rising asset turnover | 0.04 | 0.08 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| IMCC IM Cannabis Corp. compare | 4 |
| SBFM Sunshine Biopharma, Inc. compare | 4 |
| PTPI Petros Pharmaceuticals, Inc. compare | 4 |
| NEPTF Neptune Wellness Solutions Inc. compare | 3 |
| SXTC China SXT Pharmaceuticals, Inc. | 3 |
| BTAIQ BioXcel Therapeutics, Inc. compare | 2 |
| AKAN Akanda Corp. compare | 1 |
| LSDIF Lucy Scientific Discovery Inc. compare | — |
| PRFX PainReform Ltd. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover